Prosecution Insights
Last updated: April 19, 2026

Examiner: DESAI, ANAND U

Tech Center 1600 • Art Units: 1655 1656

This examiner grants 79% of resolved cases

Performance Statistics

79.3%
Allow Rate
+19.3% vs TC avg
931
Total Applications
+11.6%
Interview Lift
1217
Avg Prosecution Days
Based on 898 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%
§101 Eligibility
20.8%
§102 Novelty
18.1%
§103 Obviousness
34.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18086034 BETA-AMYLASE ENZYMES Final Rejection BASF SE
18599588 AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIUM Final Rejection Azitra Inc
17567868 METHODS FOR PREDICTING KINASE INHIBITOR RESISTANCE Final Rejection Research Development Foundation
18393339 Process for the Production of Fucosylated Oligosaccharides Non-Final OA Chr. Hansen A/S
18020068 NOVEL BACTERIAL PROTEIN FIBERS Non-Final OA NORWEGIAN UNIVERSITY OF LIFE SCIENCES
18482262 Highly Contracted Synthetic Fibroin Fiber, Production Method Therefor, and Method for Contracting Synthetic Fibroin Fiber Final Rejection Spiber Inc.
17999465 ANTIVIRAL FABRIC Non-Final OA AMOGREENTECH CO., LTD.
17792700 FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF Non-Final OA Bang Ding
18011073 IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS Non-Final OA THE HEART RESEARCH INSTITUTE LTD
17365292 METHODS FOR DESIGNING DNA BINDING PROTEIN CONTAINING PPR MOTIFS, AND USE THEREOF Final Rejection HIROSHIMA UNIVERSITY
17403846 Fusion Protein Final Rejection Viravaxx AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month